NOVAVAX INCNVAXEarnings & Financial Report
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus (RSV), avian flu, shingles, Clostridioides difficile, and malaria.
NVAX Q4 FY2025 Key Financial Metrics
Revenue
$147.3M
Gross Profit
$125.2M
Operating Profit
$14.2M
Net Profit
$17.5M
Gross Margin
85.0%
Operating Margin
9.7%
Net Margin
11.9%
YoY Growth
66.8%
EPS
$0.28
NOVAVAX INC Q4 FY2025 Financial Summary
NOVAVAX INC reported revenue of $147.3M (up 66.8% YoY) for Q4 FY2025, with a net profit of $17.5M (up 121.6% YoY) (11.9% margin). Cost of goods sold was $22.1M, operating expenses totaled $111.0M.
Key Financial Metrics
| Total Revenue | $147.3M |
|---|---|
| Net Profit | $17.5M |
| Gross Margin | 85.0% |
| Operating Margin | 9.7% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
NOVAVAX INC Q4 FY2025 revenue of $147.3M breaks down across 2 segments, led by Licensing Royalties And Other at $107.9M (73.3% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Licensing Royalties And Other | $107.9M | 73.3% |
| Products | $39.2M | 26.6% |
NOVAVAX INC Annual Revenue by Year
NOVAVAX INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.1B).
NOVAVAX INC Quarterly Revenue & Net Profit History
NOVAVAX INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $147.3M | +66.8% | $17.5M | 11.9% |
| Q3 FY2025 | $70.4M | -16.6% | $-202.4M | -287.3% |
| Q2 FY2025 | $239.2M | -42.4% | $106.5M | 44.5% |
| Q1 FY2025 | $666.5M | +610.1% | $518.6M | 77.8% |
| Q4 FY2024 | $88.3M | -69.7% | N/A | N/A |
| Q3 FY2024 | $84.5M | -54.8% | $-121.3M | -143.5% |
| Q2 FY2024 | $415.5M | -2.1% | $162.4M | 39.1% |
| Q1 FY2024 | $93.9M | +15.9% | $-147.6M | -157.2% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $93.9M | $415.5M | $84.5M | $88.3M | $666.5M | $239.2M | $70.4M | $147.3M |
| YoY Growth | 15.9% | -2.1% | -54.8% | -69.7% | 610.1% | -42.4% | -16.6% | 66.8% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.35B | $1.82B | $1.71B | $1.56B | $1.29B | $1.34B | $1.18B | $1.18B |
| Liabilities | $2.22B | $2.25B | $2.24B | $2.18B | $1.37B | $1.30B | $1.34B | $1.30B |
| Equity | $-867.1M | $-431.7M | $-526.4M | $-623.8M | $-75.6M | $37.6M | $-156.7M | $-127.8M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-83.6M | $314.3M | $-144.8M | $-87.3M | $-185.5M | $-127.5M | $107.8M | $-39.5M |